Our strategic plan is progressing towards developing a new therapeutic drug class utilizing a synthetic recombinant Platelet-Rich Plasma (PRP). This innovative approach targets various chronic diseases and is a pivotal step forward in advancing healthcare. By harnessing the power of synthetic PRP, we aim to enhance treatment options and improve patient outcomes. This milestone signifies a significant advancement in medical research and holds promise for addressing a wide range of health conditions.